

Keen to discover the *in vivo*
CRISPR technology for
hemophilia treatment?

Join our faculty in this interactive
supported symposium

Precision Therapeutics With CRISPR-Based Targeted Gene Insertion Technology: Imagining the Future of Hemophilia

Saturday, June 22, 2024

11:30 - 12:45 hrs local time | Room 209 (Level 2)

Complimentary lunch boxes will be available

Program

Welcome and Introduction

Alok Srivastava

Current Advancements in Hemophilia

Maria Elisa Mancuso

Where Are We Now: CRISPR-Based Targeted Gene Insertion

Wolfgang Miesbach

Preparing for the Future of Hemophilia: How Do We Get There

Alok Srivastava

Q&A

All Speakers


Faculty



Alok Srivastava

Christian Medical College, Vellore, India

Alok Srivastava is a Senior Professor in the Department of Hematology at the Christian Medical College, Vellore, India and head of the Center for Stem Cell Research, a unit of DBT-inStem, Bengaluru at the CMC campus in Vellore. He is also President of the Indian Association for Hemophilia & Allied Disorders and chair of the steering committee of the Association for Hemophilia and Allied Disorders - Asia-Pacific. He has led the writing group of the World Federation of Hemophilia (WFH) guidelines for the management of hemophilia. Dr. Srivastava has particularly focused his research in recent years on developing novel therapies for hemophilia, including gene therapy.



Maria Elisa Mancuso

IRCCS Humanitas Research Hospital, Center for Thrombosis and Hemorrhagic Diseases, Milan, Italy

Dr. Mancuso is a hematologist and Senior Hematology Consultant at the Center for Thrombosis and Hemorrhagic Diseases, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy and works as adjunct clinical professor at Humanitas University. Dr. Mancuso has a specific scientific interest in novel therapies, prophylaxis, inhibitors, and chronic hepatitis C. She is Vice-president of the Italian Association of Hemophilia Centers, Chair of the Medical Advisory Group of the European Hemophilia Consortium, and member of various scientific societies. She has co-chaired the SSC Subcommittee of the ISTH on FVIII, FIX, and rare bleeding disorders. She is reviewer for several peer-reviewed journals and member of the Editorial Board of the Journal of Thrombosis and Haemostasis.



Wolfgang Miesbach

Goethe University Hospital, Frankfurt, Germany

Prof. Dr. med. Miesbach is head of the Department of Coagulation Disorders and the Comprehensive Care Hemophilia Center at the Goethe University Hospital in Frankfurt am Main, Germany. In addition, he is head of the ISTH SSC Working group on gene therapy and the EAHAD Gene Therapy Working Group. Prof. Miesbach has (co-)authored a large number of peer-reviewed publications, review articles, or book chapters. His main research interests are focused on gene therapy, coagulation disorders, elderly patients with hemophilia and von Willebrand disease, and quality of life studies.

This symposium is fully sponsored by

REGENERON[®]

This symposium is for healthcare professionals only